Cefmenoxime
Appearance
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Intramuscular, intravenous |
ATC code | |
Pharmacokinetic data | |
Bioavailability | 100% (given IM) |
Protein binding | 50% to 70% |
Metabolism | Negligible |
Elimination half-life | 1 hour |
Excretion | Renal, unchanged |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H17N9O5S3 |
Molar mass | 511.562 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Cefmenoxime is a third-generation cephalosporin antibiotic.
External links
- Diseases Database (DDB): 30892
- Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T (1995). "Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis". Jpn J Antibiot. 48 (5): 602–9. PMID 7637194.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - Paladino J, Fell R (1994). "Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia". Ann Pharmacother. 28 (3): 384–9. doi:10.1177/106002809402800316. PMID 8193431.
- Duncker G, Reich U, Krausse R (1994). "Cefmenoxime in corneal organ culture". Ophthalmologica. 208 (5): 262–6. doi:10.1159/000310505. PMID 7816419.
{{cite journal}}
: CS1 maint: multiple names: authors list (link)